作者
Annie Lemelin, Marc Barritault, Valérie Hervieu, Léa Payen, Julien Péron, Anne Couvelard, Jérome Cros, Jean-Yves Scoazec, Sylvie Bin, Laurent Villeneuve, Catherine Lombard-Bohas, Thomas Walter
发表日期
2019/4/1
期刊
Digestive and Liver Disease
卷号
51
期号
4
页码范围
595-599
出版商
WB Saunders
简介
Introduction
Neuroendocrine tumors (NETs) are rare, but their incidence is rising. Alkylating agents (ALKY), temozolomide and streptozotocin, are the main chemotherapies used for advanced pancreatic NETs. According to retrospective data, O6-methylguanine-DNA methyltransferase (MGMT) status appears to be a predictive factor of the response to ALKY.
Aims
The main objective is to evaluate the value of tumor MGMT promoter (pMGMT) methylation in the prediction of the objective response (OR) at 3 months in patients treated with ALKY. Secondly, we will evaluate the value of MGMT immunohistochemistry and the efficacy of treatment with ALKY vs. oxaliplatin-based chemotherapy (Ox).
Materials and methods
A national, prospective, open-label, randomized, controlled and multicenter trial was designed. Main inclusion criteria are: adult patients with well-differentiated advanced duodeno-pancreatic, lung, or …
学术搜索中的文章
A Lemelin, M Barritault, V Hervieu, L Payen, J Péron… - Digestive and Liver Disease, 2019